NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?

 

 Buy Article Permissions and Reprints

Abstract

Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that have been associated with an increased risk of developing nonalcoholic fatty liver disease (NAFLD). Insulin resistance and central obesity are the key components of MetS, ultimately leading to liver fat accumulation and the subsequent development of necroinflammatory liver injury. However, the origin and nature of the metabolic stressors responsible for stimulating the progression of simple steatosis to nonalcoholic steatohepatitis (NASH) remain to be clearly identified. In addition, epidemiologic research on the association between MetS and NAFLD has provided only limited information to guide the development of targeted interventions, in particular, nutrition and pharmacologic prevention programs. This review summarizes the evidence supporting the proposal that NAFLD is not invariably associated with the presence of MetS, and mechanisms other than insulin resistance may contribute to the chronic inflammatory processes that underpin the development of liver fat accumulation and the subsequent architectural distortion of the liver. A special focus is given to increased hemoglobin as a risk factor for the development of NAFLD in the absence of MetS.

• References

• 1 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69 (2) 211-220
  CrossrefPubMedGoogle Scholar
• 2 Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009; 8 (Suppl 1) S18-S24
  PubMedGoogle Scholar
• 3 Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75 (10) 721-728
  CrossrefPubMedGoogle Scholar
• 4 Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1 (1) 36-40
  CrossrefPubMedGoogle Scholar
• 5 Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008; 10 (1) 73-80
  CrossrefPubMedGoogle Scholar
• 6 Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300 (5) G697-G702
  CrossrefPubMedGoogle Scholar
• 7 Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 2011; 83 (1-2) 124-133
  CrossrefPubMedGoogle Scholar
• 8 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24 (5) 695-708
  CrossrefPubMedGoogle Scholar
• 9 Lockman KA, Nyirenda MJ. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease. Curr Diabetes Rev 2010; 6 (5) 341-347
  CrossrefPubMedGoogle Scholar
• 10 Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10 (4) 412-419
  CrossrefPubMedGoogle Scholar
• 11 Kumashiro N, Erion DM, Zhang D , et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2011; 108 (39) 16381-16385
  CrossrefPubMedGoogle Scholar
• 12 Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332 (6037) 1519-1523
  CrossrefPubMedGoogle Scholar
• 13 Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011; 46 (3) 200-215
  CrossrefPubMedGoogle Scholar
• 14 Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010; 16 (17) 1941-1951
  CrossrefPubMedGoogle Scholar
• 15 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19 (10) 371-379
  CrossrefPubMedGoogle Scholar
• 16 Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14 (4) 591-604
  CrossrefPubMedGoogle Scholar
• 17 Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2011; 5 (2) 253-263
  CrossrefPubMedGoogle Scholar
• 18 Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010; 30 (4) 391-401
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60 (3) 313-326
  CrossrefPubMedGoogle Scholar
• 20 Aktas B, Yilmaz Y, Eren F , et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism 2011; 60 (4) 544-549
  CrossrefPubMedGoogle Scholar
• 21 Kukla M, Zwirska-Korczala K, Hartleb M , et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010; 45 (2) 235-242
  CrossrefPubMedGoogle Scholar
• 22 Petta S, Cammà C, Cabibi D, Di Marco V, Craxì A. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 34 (7) 757-766
  CrossrefPubMedGoogle Scholar
• 23 Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS ONE 2010; 5 (7) e11578
  CrossrefPubMedGoogle Scholar
• 24 Zimmer V, Lammert F. Genetics in liver disease: new concepts. Curr Opin Gastroenterol 2011; 27 (3) 231-239
  CrossrefPubMedGoogle Scholar
• 25 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011; 52 (4) 593-617
  CrossrefPubMedGoogle Scholar
• 26 Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5 (2) 189-200
  CrossrefPubMedGoogle Scholar
• 27 Byrne CD. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot Essent Fatty Acids 2010; 82 (4-6) 265-271
  CrossrefPubMedGoogle Scholar
• 28 Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med 2011; 9: 70
  CrossrefPubMedGoogle Scholar
• 29 Tilg H, Moschen A. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2010; 56 (2) 159-167
  PubMedGoogle Scholar
• 30 Cortez-Pinto H, Machado M. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2008; 2 (2) 217-231
  CrossrefPubMedGoogle Scholar
• 31 Marchesini G, Moscatiello S, Agostini F, Villanova N, Festi D. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs 2011; 16 (1) 121-136
  CrossrefPubMedGoogle Scholar
• 32 Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009; 11 (3) 188-195
  CrossrefPubMedGoogle Scholar
• 33 Federico A, Niosi M, Vecchio Blanco CD, Loguercio C. Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs 2008; 13 (1) 145-158
  CrossrefPubMedGoogle Scholar
• 34 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1) CD007340
  PubMedGoogle Scholar
• 35 Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6 (12) 1396-1402
  CrossrefPubMedGoogle Scholar
• 36 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21 (1) 27-41
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa?. Dig Liver Dis 2010; 42 (5) 320-330
  CrossrefPubMedGoogle Scholar
• 38 Green RM. NASH—hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003; 38 (1) 14-17
  PubMedGoogle Scholar
• 39 Adams LA, Lymp JF, St Sauver J , et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129 (1) 113-121
  CrossrefPubMedGoogle Scholar
• 40 Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290 (5) G852-G858
  CrossrefPubMedGoogle Scholar
• 41 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15 (7) 539-553
  CrossrefPubMedGoogle Scholar
• 42 Beck-Nielsen H. General characteristics of the insulin resistance syndrome: prevalence and heritability. European Group for the study of Insulin Resistance (EGIR). Drugs 1999; 58 (Suppl 1) 7-10 , discussion 75–82
  CrossrefPubMedGoogle Scholar
• 43 Grundy SM, Cleeman JI, Daniels SR , et al; American Heart Association ; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17) 2735-2752
  CrossrefPubMedGoogle Scholar
• 44 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19) 2486-2497
  CrossrefPubMedGoogle Scholar
• 45 Einhorn D, Reaven GM, Cobin RH , et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9 (3) 237-252
  PubMedGoogle Scholar
• 46 Alberti KG, Zimmet P, Shaw J ; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366 (9491) 1059-1062
  CrossrefPubMedGoogle Scholar
• 47 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005; 48 (9) 1684-1699
  CrossrefPubMedGoogle Scholar
• 48 Kahn R, Buse J, Ferrannini E, Stern M ; American Diabetes Association ; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28 (9) 2289-2304
  CrossrefPubMedGoogle Scholar
• 49 Day C. Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007; 4 (1) 32-38
  CrossrefPubMedGoogle Scholar
• 50 Tillin T, Forouhi N, Johnston DG, McKeigue PM, Chaturvedi N, Godsland IF. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectional study. Diabetologia 2005; 48 (4) 649-656
  CrossrefPubMedGoogle Scholar
• 51 Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156 (11) 1070-1077
  CrossrefPubMedGoogle Scholar
• 52 Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP ; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110 (10) 1251-1257
  CrossrefPubMedGoogle Scholar
• 53 Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007; 77 (3) 471-478
  CrossrefPubMedGoogle Scholar
• 54 Marchesini G, Bugianesi E, Forlani G , et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37 (4) 917-923
  CrossrefPubMedGoogle Scholar
• 55 Yilmaz Y, Senates E, Ayyildiz T , et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J Clin Invest 2011; ••• DOI: 10.1111/j.1365-2362.2011.02597.x.
  PubMedGoogle Scholar
• 56 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J 2008; 411 (1) 1-18
  CrossrefPubMedGoogle Scholar
• 57 Trak-Smayra V, Dargere D, Noun R , et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009; 58 (6) 825-832
  CrossrefPubMedGoogle Scholar
• 58 Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009; 58 (12) 1706-1707
  CrossrefPubMedGoogle Scholar
• 59 Yu C, Xu C, Xu L , et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012; 56 (1) 241-247
  CrossrefPubMedGoogle Scholar
• 60 Watanabe J, Chou KJ, Liao JC , et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007; 282 (32) 23698-23707
  CrossrefPubMedGoogle Scholar
• 61 Alayash AI, Patel RP, Cashon RE. Redox reactions of hemoglobin and myoglobin: biological and toxicological implications. Antioxid Redox Signal 2001; 3 (2) 313-327
  CrossrefPubMedGoogle Scholar
• 62 Leung TM, Tipoe GL, Liong EC, Lau TY, Fung ML, Nanji AA. Endothelial nitric oxide synthase is a critical factor in experimental liver fibrosis. Int J Exp Pathol 2008; 89 (4) 241-250
  CrossrefPubMedGoogle Scholar
• 63 Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009; 33 (Suppl 1) S46-S57
  CrossrefPubMedGoogle Scholar
• 64 Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS ONE 2011; 6 (9) e24363
  CrossrefPubMedGoogle Scholar
• 65 Chen SC, Yeh JJ, Chang MH , et al. Gender difference of alanine aminotransferase elevation may be associated with higher hemoglobin levels among male adolescents. PLoS ONE 2010; 5 (10) e13269
  CrossrefPubMedGoogle Scholar
• 66 Sakugawa H, Nakayoshi T, Kobashigawa K , et al. Alanine aminotransferase elevation not associated with fatty liver is frequently seen in obese Japanese women. Eur J Clin Nutr 2004; 58 (9) 1248-1252
  CrossrefPubMedGoogle Scholar
• 67 Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis 2010; 28 (1) 210-213
  CrossrefPubMedGoogle Scholar
• 68 Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8 (Suppl 1) S40-S43
  CrossrefPubMedGoogle Scholar
• 69 Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond) 2008; 115 (1) 1-12
  CrossrefPubMedGoogle Scholar
• 70 Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008; 49 (4) 600-607
  CrossrefPubMedGoogle Scholar
• 71 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363 (14) 1341-1350
  CrossrefPubMedGoogle Scholar
• 72 Carter C, McGee D, Reed D, Yano K, Stemmermann G. Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program. Am Heart J 1983; 105 (4) 674-679
  CrossrefPubMedGoogle Scholar
• 73 Campbell MJ, Elwood PC, Mackean J, Waters WE. Mortality, haemoglobin level and haematocrit in women. J Chronic Dis 1985; 38 (10) 881-889
  CrossrefPubMedGoogle Scholar
• 74 Sorlie PD, Garcia-Palmieri MR, Costas Jr R, Havlik RJ. Hematocrit and risk of coronary heart disease: the Puerto Rico Health Program. Am Heart J 1981; 101 (4) 456-461
  CrossrefPubMedGoogle Scholar
• 75 Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease—the Framingham Study: a 34-year follow-up. Am Heart J 1994; 127 (3) 674-682
  CrossrefPubMedGoogle Scholar
• 76 Smith S, Julius S, Jamerson K, Amerena J, Schork N. Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan. J Hypertens 1994; 12 (4) 455-462
  PubMedGoogle Scholar
• 77 Burch GE, DePasquale NP. Hematocrit, viscosity and coronary blood flow. Dis Chest 1965; 48 (3) 225-232
  CrossrefPubMedGoogle Scholar
• 78 Lowe GD, Forbes CD. Platelet aggregation, haematocrit, and fibrinogen. Lancet 1985; 1 (8425) 395-396
  PubMedGoogle Scholar
• 79 Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86 (3) 803-811
  CrossrefPubMedGoogle Scholar
• 80 Tong PC, Kong AP, So WY , et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. Diabetes Care 2006; 29 (11) 2439-2444
  CrossrefPubMedGoogle Scholar
• 81 Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J 2001; 142 (4) 657-663
  CrossrefPubMedGoogle Scholar